Your fact-checks will appear here
Agency of the European Union
Early real-world studies from the United Kingdom and pooled European surveillance indicate that the 2025–26 seasonal influenza vaccine retains meaningful protection against the emergent H3N2 subclade ...
Europe is seeing early, rising influenza activity dominated by A(H3N2) “subclade K” (formerly J.2.4.1), which accounted for about one-third of global A/H3N2 sequences May–Nov 2025 and “almost half” of...
Europe is experiencing an early, H3N2-dominated 2025–26 influenza season driven largely by a drifted H3N2 “subclade K,” which accounts for about one‑third of global H3N2 sequences and almost half of H...
Early real-world data from the UK indicate the 2025–26 vaccine is reducing hospital attendance for pediatric H3N2 cases by about 70–75% and by roughly 30–40% in adults, even as a drifted H3N2 “subclad...
A mutated H3N2 influenza — called subclade K or “K” — has driven an unusually early, intense flu season in parts of the Northern Hemisphere, dominating samples in the UK and appearing across continent...
Major public health agencies do not report a single, verified global death toll that is causally attributed to COVID‑19 vaccines; monitoring systems record rare reports and specific ICD‑10 coding in s...
Global reporting in 2023 shows wide variation in COVID-19 vaccination by metric: some countries led the world on cumulative doses per 100 people (Cuba was cited near the top with ~391 doses/100 by Mar...
Early real-world data from the UK show the 2025–26 vaccine is reducing hospital attendance for children aged 2–17 by roughly 70–75% and protecting adults at substantially lower levels—about 30–40% aga...
Genetic and antigenic analyses from surveillance groups and recent papers show that H3N2 viruses acquired multiple mutations in 2024–2025 and a newly named “subclade K” (bearing ~7 key HA changes incl...
US immunization guidance has shifted in 2025 from blanket, population-level directives toward more “individual-based decision‑making” for some vaccines: the CDC updated its schedules in October to app...
Antivirals available this season include neuraminidase inhibitors (oseltamivir, zanamivir, peramivir) and the cap-dependent endonuclease inhibitor baloxavir; guidance and surveillance note good retain...
Real‑world UK data show the 2025–26 seasonal vaccine—designed with different H3N2 strains for egg‑based and for cell/recombinant products—still provided substantial protection against severe outcomes ...
WHO’s advisory group recommended A/Croatia/10136RV/2023-like as the A(H3N2) component for Northern Hemisphere 2025–26 trivalent (egg-based) vaccines; WHO also selected different H3N2 candidates for So...
As of the provided analyses, ; instead the material reports vaccine uptake for specific groups and regional surveillance snapshots. The strongest consolidated facts are that WHO member-state reporting...
Early, real‑world UK and England analyses show the 2025–26 trivalent vaccine is reducing severe outcomes from circulating A(H3N2) subclade K: vaccine effectiveness (VE) against hospital attendance/adm...
Seek medical help for low body temperature (hypothermia) after flu or COVID if you have ongoing confusion, difficulty breathing, chest pain, fainting, or your temperature is persistently very low — es...
Early, multi-country data indicate the 2025–2026 seasonal vaccines provide meaningful but imperfect protection against the emergent H3N2 J.2.4.1 (subclade K): strong protection in children (roughly 72...
Multiple independent surveillance and laboratory reports find that H3N2 subclade K remains susceptible to the licensed influenza antivirals now in clinical use, even as the variant has antigenically d...
Influenza A(H3N2) subclade K (formerly J.2.4.1) emerged visibly in August 2025 in Australia and New Zealand and has since seeded rapid global spread, being detected in more than 34 countries and on al...
A(H3N2) “subclade K” (also called J.2.4.1) has surged globally since August 2025 and now dominates many regional sequences, including the United States and Europe . Public-health agencies nonetheless ...